Skip to Content
Merck
All Photos(1)

Key Documents

807473

Supelco

TOYOPEARL® DEAE-650M Bulk Media

phase DEAE (diethylaminoethyl), bottle of 250 mL, 65 μm particle size

Synonym(s):

TOYOPEARL® DEAE-650M Bulk Media

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
47101511

description

DEAE-650M

form

slurry

feature

counter ion Cl-

packaging

bottle of 250 mL

parameter

3 bar max. pressure

technique(s)

HPLC: suitable

matrix

methacrylate

matrix active group

DEAE (diethylaminoethyl) phase

particle size

65 μm

operating pH

2-10

capacity

0.10 meq/mL±0.02 meq/mL ion exchange capacity
 30 g/L±5 adsorption capacity (BSA)
 30 mg/mL±5 mg/mL binding capacity (bovine serum albumin)

compatibility

mode of use weak anion exchange chromatography

separation technique

anion exchange

General description

Toyopearl DEAE-650 resin is a weak anion exchanger for blood fractionation and other biomolecule purification. It can be used for high throughput capture, intermediate purification, and polishing process steps. If more powerful resolution is needed TSKgel DEAE-5PW resin should be used. Selectivity remains the same.

Application

TOYOPEARL® DEAE-650M is used in separation media and ion exchange resins. TOYOPEARL® DEAE-650M has been used in haemophilia studies.

Specifications

Clean in place with 0.5 M NaOH or 0.1 M HCl.

Physical form

Shipped in 20% (v/v) ethanol.

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Toyopearl is a registered trademark of Tosoh Corporation

Pictograms

Flame
GHS02

Signal Word

Warning

Hazard Statements

H226

Hazard Classifications

Flam. Liq. 3

WGK

WGK 1

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
107H0708

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

P R Foster et al.
Vox sanguinis, 86(2), 92-99 (2004-03-17)
The risk of haemophiliacs contracting variant Creutzfeldt-Jakob disease (vCJD) via treatment with factor VIII concentrates is not known. Therefore, in order to determine the extent to which the vCJD agent might be removed during the preparation of factor VIII concentrate
Christine Machold et al.
Journal of biotechnology, 117(1), 83-97 (2005-04-16)
Two different approaches of matrix assisted refolding have been evaluated and compared to conventional refolding by dilution. Bovine alpha-lactalbumin was used for the studies as model protein. It was adsorbed under denaturing conditions on an ion exchange matrix and refolding
Masahiko Takanashi et al.
Journal of bioscience and bioengineering, 97(1), 78-81 (2005-10-20)
D(-)-3-hydroxybutyrate dehydrogenase (BDH; EC 1.1.1.30) from a poly(D(-)-3-hydroxybutyrate) (PHB) degrading bacterium, Acidovorax sp. SA1, was purified using Toyopearl DEAE-650M, red-Sepharose CL-4B, and Q Sepharose FF. The molecular mass of the enzyme was estimated as 27 kDa by SDS-PAGE and 110
Günter Iberer et al.
Journal of chromatography. A, 972(1), 115-129 (2002-10-25)
Preparative continuous annular chromatography, a method to separate proteins in a truly continuous manner, was investigated in an industrial environment. Plasma-derived clotting factor IX concentrate was used as model protein. Separation of vitronectin, a common impurity in commercial available factor

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service